Marianne Grønlie Guren

• Sodergren, S.C.; Hurley-Wallace, A.; Vassiliou, V.; Alkhaffaf, B.; Batsaikhan, B. & Darlington, A.S. [Show all 21 contributors for this article] (2024). Revisiting the use of the EORTC QLQ-STO22 to assess health-related quality of life of patients with gastric cancer: incorporating updated treatment options and cross-cultural perspectives. Gastric Cancer. ISSN 1436-3291. doi: 10.1007/s10120-024-01492-8.
• Ree, Anne Hansen; Saltyte Benth, Jurate; Hamre, Hanne Mari; Kersten, Christian; Hofsli, Eva & Guren, Marianne [Show all 14 contributors for this article] (2024). First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial. British Journal of Cancer. ISSN 0007-0920. doi: 10.1038/s41416-024-02696-6.
• McPhail, Sean; Barclay, Matthew E; Johnson, Shane A; Swann, Ruth; Alvi, Riaz & Barisic, Andriana [Show all 34 contributors for this article] (2024). Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study. The Lancet Oncology. ISSN 1470-2045. 25(3), p. 338–351. doi: 10.1016/S1470-2045(24)00031-7.
• Roa, ana Maria Acosta; Skingen, Vilde Eide; Rekstad, Bernt Louni; Undseth, Christine; Rusten, Espen & Hernes, Eivor [Show all 8 contributors for this article] (2023). Stability of metabolic tumor volume may enable radiotherapy dose painting in anal cancer. Physica Medica. ISSN 1120-1797. 114, p. 1–7. doi: 10.1016/j.ejmp.2023.103151. Full text in Research Archive
• Niyoteka, Stephane; Seban, Romain-David; Rouhi, Rahimeh; Scarsbrook, Andrew; Genestie, Catherine & Classe, Marion [Show all 19 contributors for this article] (2023). A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers. European Journal of Nuclear Medicine and Molecular Imaging. ISSN 1619-7070. doi: 10.1007/s00259-023-06320-2. Full text in Research Archive
• Nilsson, Martin P.; Undseth, Christine; Albertsson, Per; Eidem, Monica; Havelund, Birgitte Mayland & Johannsson, Jakob [Show all 13 contributors for this article] (2023). Nordic anal cancer (NOAC) group consensus guidelines for risk-adapted delineation of the elective clinical target volume in anal cancer. Acta Oncologica. ISSN 0284-186X. 62(8), p. 897–906. doi: 10.1080/0284186X.2023.2240490. Full text in Research Archive
• Hanekamp, Bettina; Viktil, Ellen; Slørdahl, Kathinka; Dormagen, Johann Baptist; Kløw, Nils-Einar & Malinen, Eirik [Show all 9 contributors for this article] (2023). Magnetic resonance imaging of anal cancer: tumor characteristics and early prediction of treatment outcome. Strahlentherapie und Onkologie (Print). ISSN 0179-7158. p. 1–9. doi: 10.1007/s00066-023-02114-5. Full text in Research Archive
• Segelov, Eva; Guren, Marianne; Sebag-Montefiore, David; Rao, Sheela; Johnsson, Anders & Franco, Pierfrancesco [Show all 9 contributors for this article] (2022). "Global multidisciplinary team meetings": Challenging cases virtual forums from the International Multidisciplinary Anal Cancer Conference (IMACC). Clinical colorectal cancer. ISSN 1533-0028. 21(3), p. 175–187. doi: 10.1016/j.clcc.2022.02.006.
• Sodergren, Samantha C.; Johnson, Colin D.; Gilbert, Alexandra; Darlington, Anne-Sophie; Cocks, Kim & Guren, Marianne [Show all 29 contributors for this article] (2022). International Validation of the EORTC QLQ-ANL27, a Field Study to Test the Anal Cancer–Specific Health-Related Quality of Life Questionnaire. International Journal of Radiation Oncology, Biology, Physics. ISSN 0360-3016. doi: 10.1016/j.ijrobp.2022.11.002.
• Meltzer, Sebastian; Negård, Anne; Bakke, Kine Mari; Hamre, Hanne Mari; Kersten, Christian & Hofsli, Eva [Show all 10 contributors for this article] (2022). Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer. British Journal of Cancer. ISSN 0007-0920. 127, p. 2227–2233. doi: 10.1038/s41416-022-02004-0. Full text in Research Archive
• Rao, S.; Anandappa, G.; Capdevila, J.; Dahan, L.; Evesque, L. & Kim, S. [Show all 22 contributors for this article] (2022). A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open. ISSN 2059-7029. 7(4). doi: 10.1016/j.esmoop.2022.100529. Full text in Research Archive
• Bahadoer, Renu R.; Bastiaannet, Esther; Peeters, Koen C.M.J.; van Eycken, Elizabeth; Verbeeck, Julie & Guren, Marianne [Show all 11 contributors for this article] (2022). The survival gap between young and older patients after surgical resection for colorectal cancer remains largely based on early mortality: A EURECCA comparison of four European countries. Journal of Geriatric Oncology. ISSN 1879-4068. 13(6), p. 803–812. doi: 10.1016/j.jgo.2022.04.011.
• Rowsell, Alison; Sodergren, Samantha C.; Vassiliou, Vassilios; Darlington, Anne-Sophie; Guren, Marianne & Alkhaffaf, Bilal [Show all 9 contributors for this article] (2022). Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences. Gastric Cancer. ISSN 1436-3291. 25(4), p. 665–677. doi: 10.1007/s10120-022-01309-6. Full text in Research Archive
• Kørner, Hartwig; Guren, Marianne; Larsen, Inger Kristin; Haugen, Dagny Renata Faksvåg; Søreide, Kjetil & Kørner, Leif Roland [Show all 7 contributors for this article] (2022). Characteristics and fate of patients with rectal cancer not entering a curative-intent treatment pathway: A complete nationwide registry cohort of 3,304 patients. European Journal of Surgical Oncology. ISSN 0748-7983. 48(8), p. 1831–1839. doi: 10.1016/j.ejso.2022.04.013. Full text in Research Archive
• Dijkstra, Esmée A.; Hospers, Geke A.P.; Kranenbarg, Elma Meershoek-Klein; Fleer, Joke; Roodvoets, Annet G.H. & Bahadoer, Renu R. [Show all 18 contributors for this article] (2022). Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer – The RAPIDO trial. Radiotherapy and Oncology. ISSN 0167-8140. 171, p. 69–76. doi: 10.1016/j.radonc.2022.04.013. Full text in Research Archive
• Falk, Philip; Severin, Mira; Berglund, Åke; Guren, Marianne; Hofsli, Eva & Österlund, Pia [Show all 9 contributors for this article] (2022). Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. Cancer Treatment and Research Communications. ISSN 2468-2942. 31, p. 100517–100517. doi: 10.1016/j.ctarc.2022.100517. Full text in Research Archive
• Franco, Pierfrancesco; Segelov, Eva; Johnsson, Anders; Riechelmann, Rachel; Guren, Marianne & Das, Prajnan [Show all 14 contributors for this article] (2022). A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer. Cancers. ISSN 2072-6694. 14(7). doi: 10.3390/cancers14071697. Full text in Research Archive
• Nilssen, Yngvar; Brustugun, Odd Terje; Eriksen, Morten Tandberg; Guren, Marianne; Haug, Erik Skaaheim & Naume, Bjørn [Show all 8 contributors for this article] (2022). Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016. BMC Cancer. ISSN 1471-2407. 22(220). doi: 10.1186/s12885-022-09306-9. Full text in Research Archive Show summary

  Background Cancer patient pathways (CPPs) were implemented in Norway to reduce unnecessary waiting times, regional variations, and to increase the predictability of cancer care for the patients. This study aimed to determine if 70% of cancer patients started treatment within the recommended time frames, and to identify potential delays. Methods Patients registered with a colorectal, lung, breast, or prostate cancer diagnosis at the Cancer Registry of Norway in 2015–2016 were linked with the Norwegian Patient Registry and Statistics Norway. Adjusting for sociodemographic variables, multivariable quantile (median) regressions were used to examine the association between place of residence and median time to start of examination, treatment decision, and start of treatment. Results The study included 20 668 patients. The proportions of patients who went through the CPP within the recommended time frames were highest among colon (84%) and breast (76%) cancer patients who underwent surgery and lung cancer patients who started systemic anticancer treatment (76%), and lowest for prostate cancer patients who underwent surgery (43%). The time from treatment decision to start of treatment was the main source of delay for all cancers. Travelling outside the resident health trust prolonged waiting time and was associated with a reduced odds of receiving surgery and radiotherapy for lung and rectal cancer patients, respectively. Conclusions Achievement of national recommendations of the CCP times differed by cancer type and treatment. Identified bottlenecks in the pathway should be targeted to decrease waiting times. Further, CPP guidelines should be re-examined to determine their ongoing relevance.

• Zaborowski, Alexandra M.; Abdile, Ahmed; Adamina, Michel; Aigner, Felix; D'Allens, Laura & Allmer, Caterina [Show all 221 contributors for this article] (2021). Characteristics of Early-Onset vs Late-Onset Colorectal Cancer: A Review. JAMA Surgery. ISSN 2168-6254. 156(9), p. 865–874. doi: 10.1001/jamasurg.2021.2380.
• Rao, Sheela; Guren, Marianne Grønlie; Khan, K; Brown, Gina; Renehan, Andrew & Steigen, Sonja Eriksson [Show all 9 contributors for this article] (2021). Anal cancer: ESMO clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. ISSN 0923-7534. 32(9), p. 1087–1100. doi: 10.1016/j.annonc.2021.06.015.
• Hamfjord, Julian; Myklebust, Tor Åge; Larsen, Inger Kristin; Kure, Elin Wenche Hegland; Glimelius, Bengt & Guren, Tormod Kyrre [Show all 8 contributors for this article] (2021). Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study. Cancer Epidemiology, Biomarkers and Prevention. ISSN 1055-9965. 31(2), p. 342–351. doi: 10.1158/1055-9965.EPI-21-0555. Full text in Research Archive Show summary

  Background: Patients with right-sided colon cancer (RCC) and left-sided colon cancer (LCC) differ clinically and molecularly. The main objective was to investigate stage-stratified survival and recurrence of RCC and LCC across four 10-year periods. Methods: Patients diagnosed from 1977 to 2016 with colon adenocarcinoma were included from the Cancer Registry of Norway. Primary tumor location (PTL) was defined as RCC if proximal and LCC if distal to the splenic flexure. Multivariable regressions were used to estimate HRs for overall survival (OS), recurrence-free survival (RFS), survival after recurrence (SAR), and excess HRs (eHR) for relative survival (RS). Results: 72,224 patients were eligible for analyses [55.1% (n = 39,769/72,224) had RCC]. In 1977 to 1986, there was no difference between LCC and RCC in OS [HR, 1.01; 95% confidence interval (CI), 0.97–1.06; P = 0.581] or RS (eHR, 0.96; 95% CI, 0.90–1.02; P = 0.179). In 2007 to 2016, LCC had significantly better OS (HR, 0.84; 95% CI, 0.80–0.87; P < 0.001) and RS (eHR, 0.76; 95% CI, 0.72–0.81; P < 0.001) compared with RCC. The gradually diverging and significantly favorable prognosis for LCC was evident for distant disease across all time periods and for regional disease from 2007 onward. There was no difference in RFS between LCC and RCC in patients less than 75 years during 2007 to 2016 (HR, 0.99; 95% CI, 0.91–1.08; P = 0.819); however, SAR was significantly better for LCC (HR, 0.61; 95% CI, 0.53–0.71; P < 0.001). Conclusions: A gradually diverging and increasingly favorable prognosis was observed for patients with LCC with advanced disease over the past four decades. Impact: Current PTL survival disparities stress the need for further exploring targetable molecular subgroups across and within different PTLs to further improve patient outcomes.

• Bruun, Jarle; Eide, Peter Andreas Wold; Bergsland, Christian Holst; Brück, Oscar; Svindland, Aud & Arjama, Mariliina [Show all 13 contributors for this article] (2021). E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. Molecular Oncology. ISSN 1574-7891. 00, p. 1–18. doi: 10.1002/1878-0261.13159. Full text in Research Archive
• Guren, Marianne; Sebag-Montefiore, David; Franco, Pierfrancesco; Johnsson, Anders; Segelov, Eva & Deutsch, Eric [Show all 9 contributors for this article] (2021). Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. Clinical colorectal cancer. ISSN 1533-0028. 20(4), p. 279–287. doi: 10.1016/j.clcc.2021.09.006. Show summary

  Anal cancer is a relatively rare, mostly HPV-related cancer. The curative treatment consists of concurrent chemoradiation delivered with modern radiotherapy techniques. The prognosis for most patients with early localized disease is very favourable; however patients with locally advanced disease and/or HPV negative tumours are at higher risk of locoregional and distant treatment failure. Tailored approaches are presently being investigated to determine the most suitable regimen in terms of radiotherapy dose prescription, target volume selection, normal tissue avoidance, and combination therapy. Metastatic anal cancer is treated with chemotherapy aiming at prolonged survival. The role of immune therapy in the clinical setting is being investigated. There is little knowledge on the biology of anal cancer, and an urgent need for more clinical and translational research dedicated to this disease. In this article, the evidence-base for the current treatment is briefly reviewed, and perspectives on future research needs are high-lighted.

• Rønde, Heidi S.; Kallehauge, Jesper F; Kronborg, Camilla; Nyvang, L; Rekstad, Bernt Louni & Hanekamp, Bettina [Show all 9 contributors for this article] (2021). Intensity modulated proton therapy planning study for organ at risk sparing in rectal cancer re-irradiation. Acta Oncologica. ISSN 0284-186X. 60(11), p. 1436–1439. doi: 10.1080/0284186X.2021.1953139.
• Moosavi, Seyed Hossein; Eide, Peter Andreas Wold; Eilertsen, Ina Andrassy; Brunsell, Tuva Høst; Berg, Kaja Christine Graue & Røsok, Bård Ingvald [Show all 12 contributors for this article] (2021). De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. Genome Medicine. ISSN 1756-994X. 13, p. 143–143. doi: 10.1186/s13073-021-00956-1. Full text in Research Archive
• Slørdahl, Kathinka; Klotz, Dagmar; Olsen, Jan Åge; Skovlund, Eva; Undseth, Christine & Abildgaard, Heidi L. [Show all 17 contributors for this article] (2021). Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. Acta Oncologica. ISSN 0284-186X. 60(7), p. 921–930. doi: 10.1080/0284186X.2021.1918763. Full text in Research Archive
• Choudhury, Ananya; Theophanous, Stelios; Lønne, Per-Ivar; Samuel, Robert; Guren, Marianne Grønlie & Berbee, Maaike [Show all 14 contributors for this article] (2021). Predicting outcomes in anal cancer patients using multi-centre data and distributed learning - A proof-of-concept study. Radiotherapy and Oncology. ISSN 0167-8140. 159, p. 183–189. doi: 10.1016/j.radonc.2021.03.013.
• Österman, Erik; Ekström, Joakim; Sjöblom, Tobias; Kørner, Hartwig; Myklebust, Tor Åge & Guren, Marianne [Show all 7 contributors for this article] (2021). Accurate population-based model for individual prediction of colon cancer recurrence. Acta Oncologica. ISSN 0284-186X. 60(10), p. 1241–1249. doi: 10.1080/0284186X.2021.1953138. Show summary

  Background Prediction models are useful tools in the clinical management of colon cancer patients, particularly when estimating the recurrence rate and, thus, the need for adjuvant treatment. However, the most used models (MSKCC, ACCENT) are based on several decades-old patient series from clinical trials, likely overestimating the current risk of recurrence, especially in low-risk groups, as outcomes have improved over time. The aim was to develop and validate an updated model for the prediction of recurrence within 5 years after surgery using routinely collected clinicopathologic variables. Material and methods A population-based cohort from the Swedish Colorectal Cancer Registry of 16,134 stage I–III colon cancer cases was used. A multivariable model was constructed using Cox proportional hazards regression. Three-quarters of the cases were used for model development and one quarter for internal validation. External validation was performed using 12,769 stage II–III patients from the Norwegian Colorectal Cancer Registry. The model was compared to previous nomograms. Results The nomogram consisted of eight variables: sex, sidedness, pT-substages, number of positive and found lymph nodes, emergency surgery, lymphovascular and perineural invasion. The area under the curve (AUC) was 0.78 in the model, 0.76 in internal validation, and 0.70 in external validation. The model calibrated well, especially in low-risk patients, and performed better than existing nomograms in the Swedish registry data. The new nomogram’s AUC was equal to that of the MSKCC but the calibration was better. Conclusion The nomogram based on recently operated patients from a population registry predicts recurrence risk more accurately than previous nomograms. It performs best in the low-risk groups where the risk-benefit ratio of adjuvant treatment is debatable and the need for an accurate prediction model is the largest.

• Grøndahl, Aurora Rosvoll; Moe, Yngve Mardal; Kaushal, Christine Kiran; Huynh, Bao Ngoc; Rusten, Espen & Tomic, Oliver [Show all 12 contributors for this article] (2021). Deep learning-based automatic delineation of anal cancer gross tumour volume: a multimodality comparison of CT, PET and MRI. Acta Oncologica. ISSN 0284-186X. 61(1), p. 89–96. doi: 10.1080/0284186X.2021.1994645.
• Nilssen, Yngvar; Eriksen, Morten Tandberg; Guren, Marianne G. & Møller, Bjørn (2021). Factors associated with emergency-onset diagnosis, time to treatment and type of treatment in colorectal cancer patients in Norway. BMC Cancer. ISSN 1471-2407. 21(1). doi: 10.1186/s12885-021-08415-1. Full text in Research Archive
• Kryeziu, Kushtrim; Moosavi, Seyed Hossein; Bergsland, Christian Holst; Guren, Marianne; Eide, Peter Andreas Wold & Totland, Max [Show all 11 contributors for this article] (2021). Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. Journal of Translational Medicine. ISSN 1479-5876. 19:384, p. 1–11. doi: 10.1186/s12967-021-03062-3. Full text in Research Archive
• Torstveit, Ann Helen; Miaskowski, Christine; Løyland, Borghild; Grov, Ellen Karine; Guren, Marianne Grønlie & Ritchie, Christine Seel [Show all 9 contributors for this article] (2021). Common and distinct characteristics associated with self-reported functional status in older patients with cancer receiving chemotherapy. European Journal of Oncology Nursing. ISSN 1462-3889. 54:102033, p. 1–10. doi: 10.1016/j.ejon.2021.102033. Show summary

  ABSTRACT Purpose: Functional impairment has a negative impact on older patients with cancer. Objectives: Evaluate for inter-individual differences in two subjective measures of functional status in older patients (n = 112); to determine which demographic, clinical, and symptom characteristics, and levels of cognitive function, were associated with initial levels and with the trajectory of the two measures. Methods: Functional status was assessed using self-report measures of physical function (PF) and role function (RF) from the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire at the initiation of chemotherapy and at 1, 3, 6, 9, and 12 months after its initiation. Hierarchical linear modeling was used to assess inter-individual differences in and characteristics associated with initial levels and changes in PF and RF. Results: Characteristics associated with decreases in PF at the initiation of chemotherapy were higher numbers of comorbidities and higher depression, pain, and dyspnea scores. For initial levels of poorer RF, lower Karnofsky Performance Status scores and higher pain and fatigue scores were the associated characteristics. Characteristic associated with worse trajectories of PF was not having had surgery. For RF, worse trajectories were associated with lower cognitive function and higher RF at enrollment. Characteristic associated with both lower initial levels and improved trajectories of PF was having lower performance status at enrollment. Conclusions: Older patients undergoing chemotherapy experience reduced functional performance. Characteristics associated with decrements in PF and RF need to be assessed and interventions implemented to maintain and increase functional status in older oncology patients.

• Bahadoer, Renu R.; Bastiaannet, Esther; Claassen, Yvette H.M.; van der Mark, Marianne; van Eycken, Elizabeth & Verbeeck, Julie [Show all 12 contributors for this article] (2021). One-year excess mortality and treatment in surgically treated patients with colorectal cancer: A EURECCA European comparison. European Journal of Surgical Oncology. ISSN 0748-7983. p. 1–10. doi: 10.1016/j.ejso.2021.01.011.
• Torstveit, Ann Helen; Løyland, Borghild; Grov, Ellen Karine; Guren, Marianne; Paul, Steven M. & Ritchie, Christine [Show all 9 contributors for this article] (2021). Distinctions Between Self-Report and Performance-Based Measures of Physical Function in Older Patients Prior to Chemotherapy. Cancer Nursing. ISSN 0162-220X. 44(6), p. E735–E744. doi: 10.1097/ncc.0000000000000964. Show summary

  ABSTRACT Background: The maintenance of physical function (PF) is an extremely important outcome for older adults. Objective: The aims of this study were to, identify differences in subjective and objective measures of PF between younger older adults (YOA, 60-69 years of age) and older adults (OA, ≥70 years of age); compare the PF scores with age-matched samples from the general population; and evaluate for associations between subjective and objective measures of PF. Methods: Patients (n=139) were assessed using subjective (i.e., European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire (QLQ-C30)) and objective (i.e., Short Physical Performance Battery (SPPB)) measures prior to chemotherapy (CTX). Data were analyzed using parametric and nonparametric tests. Results: No differences were found between the two age groups in any of the subjective or objective measures of PF. Compared to the age-matched general population; both YOA and OA had significantly lower scores in both measures of PF. Large effect sizes were found for differences in QLQ-C30 role function, SPPB balance, and SPPB total scores between the YOA group and the age-matched general population samples. Correlations between the subjective and objective measures were low. Conclusions: Older patients with cancer have lower PF than their age matched general population prior to CTX. Longitudinal studies are warranted to evaluate for changes in PF during and following CTX. Implications for Practice: Nurses need to perform routine assessments of PF in older oncology patients prior to CTX. Our findings suggest that SPPB gait speed may be a useful screening measure for PF in older patients.

• Marijnen, Corrie A.M.; Peters, F P; Rödel, Claus; Bujko, K; Haustermans, Karin & Fokas, Emmanouil [Show all 15 contributors for this article] (2020). International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiotherapy and Oncology. ISSN 0167-8140. 148, p. 213–215. doi: 10.1016/j.radonc.2020.03.039.
• Bruun, Jarle; Kryeziu, Kushtrim; Eide, Peter Andreas Wold; Moosavi, Seyed Hossein; Eilertsen, Ina Andrassy & Røsok, Bård Ingvald [Show all 21 contributors for this article] (2020). Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. Clinical Cancer Research. ISSN 1078-0432. 26(15), p. 4107–4119. doi: 10.1158/1078-0432.CCR-19-3637. Show summary

  Abstract Purpose: Molecular tumor heterogeneity may have important implications for the efficacy of targeted therapies in metastatic cancers. Inter-metastatic heterogeneity of sensitivity to anticancer agents has not been well explored in colorectal cancer. Experimental Design: We established a platform for ex vivo pharmacogenomic profiling of patient-derived organoids (PDO) from resected colorectal cancer liver metastases. Drug sensitivity testing (n = 40 clinically relevant agents) and gene expression profiling were performed on 39 metastases from 22 patients. Results: Three drug–response clusters were identified among the colorectal cancer metastases, based primarily on sensitivities to EGFR and/or MDM2 inhibition, and corresponding with RAS mutations and TP53 activity. Potentially effective therapies, including off-label use of drugs approved for other cancer types, could be nominated for eighteen patients (82%). Antimetabolites and targeted agents lacking a decisive genomic marker had stronger differential activity than most approved chemotherapies. We found limited intra-patient drug sensitivity heterogeneity between PDOs from multiple (2–5) liver metastases from each of ten patients. This was recapitulated at the gene expression level, with a highly proportional degree of transcriptomic and pharmacological variation. One PDO with a multi-drug resistance profile, including resistance to EGFR inhibition in a RAS-mutant background, showed sensitivity to MEK plus mTOR/AKT inhibition, corresponding with low-level PTEN expression. Conclusions: Intra-patient inter-metastatic pharmacological heterogeneity was not pronounced and ex vivo drug screening may identify novel treatment options for metastatic colorectal cancer. Variation in drug sensitivities was reflected at the transcriptomic level, suggesting potential to develop gene expression–based predictive signatures to guide experimental therapies.

• Breugom, Anne J.; Bastiaannet, Esther; Guren, Marianne; Kørner, Hartwig; Boelens, Petra G. & Dekker, Friedo W. [Show all 11 contributors for this article] (2020). Treatment strategies and overall survival for incurable metastatic colorectal cancer – A EURECCA international comparison including 21,196 patients from the Netherlands and Norway. European Journal of Surgical Oncology. ISSN 0748-7983. 46(6), p. 1167–1173. doi: 10.1016/j.ejso.2020.02.005.
• Rao, Sheela; Sclafani, Francesco; Eng, Cathy; Adams, Richard A; Guren, Marianne & Sebag-Montefiore, David [Show all 21 contributors for this article] (2020). International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. Journal of Clinical Oncology. ISSN 0732-183X. 38(22), p. 2510–2518. doi: 10.1200/JCO.19.03266. Show summary

  PURPOSE To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS Patients who had not received systemic therapy for advanced anal cancer were randomly assigned 1:1 to intravenous cisplatin 60 mg/m2 (day 1) plus FU 1,000 mg/m2 (days 1-4) every 21 days or carboplatin (area under the curve, 5; day 1) plus paclitaxel 80 mg/m2 (days 1, 8, and 15) every 28 days for 24 weeks, until disease progression, intolerable toxicity, or withdrawal of consent. Primary end point was objective response rate (ORR). Primary and secondary end points were assessed in a hierarchic model to compare the regimens and pick the winner. RESULTS We conducted an international multicenter randomized phase II study in 60 centers between December 2013 and November 2017. Median follow-up was 28.6 months. A total of 91 patients were randomly assigned: 46 to cisplatin plus FU and 45 to carboplatin plus paclitaxel. ORR was 57% (95% CI, 39.4% to 73.7%) for cisplatin plus FU versus 59% (95% CI, 42.1% to 74.4%) for carboplatin plus paclitaxel. More serious adverse events were noted in the cisplatin plus FU arm (62%) compared with the carboplatin plus paclitaxel arm (36%; P = .016). Median progression-free survival was 5.7 months (95% CI, 3.3 to 9.0 months) for cisplatin plus FU compared with 8.1 months (95% CI, 6.6 to 8.8 months) for carboplatin plus paclitaxel. Median overall survival was 12.3 months for cisplatin plus FU (95% CI, 9.2 to 17.7 months) compared with 20 months (95% CI, 12.7 months to not reached) for carboplatin plus paclitaxel (hazard ratio, 2.00; 95% CI, 1.15 to 3.47; P = .014). CONCLUSION This is the first international randomized trial to our knowledge conducted in chemotherapy-naïve advanced anal cancer. Although there was no difference in ORR, the association with clinically relevant reduced toxicity and a trend toward longer survival suggest that carboplatin plus paclitaxel should be considered as a new standard of care.

• Dahl, Olav; Myklebust, Mette Pernille; Dale, Jon Espen; Leon, Otilia; Serup-Hansen, Eva & Jakobsen, Anders [Show all 13 contributors for this article] (2020). Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. Acta Oncologica. ISSN 0284-186X. 59(9), p. 1016–1023. doi: 10.1080/0284186X.2020.1778180.
• Araghi, Marzieh; Arnold, Melina; Rutherford, Mark J.; Guren, Marianne; Cabasag, Citadel J. & Bardot, Aude [Show all 25 contributors for this article] (2020). Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut. ISSN 0017-5749. 70(1), p. 114–126. doi: 10.1136/gutjnl-2020-320625.
• Pilleron, Sophie; Charvat, Hadrien; Araghi, Marzieh; Arnold, Melina; Fidler-Benaoudia, Miranda M. & Bardot, Aude [Show all 20 contributors for this article] (2020). Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study. International Journal of Cancer. ISSN 0020-7136. 148(7), p. 1575–1585. doi: 10.1002/ijc.33326.
• Kværner, Ane Sørlie; Harnæs, Helene; Alavi, Dena Helene; Bärebring, Linnea; Henriksen, Hege & Guren, Marianne [Show all 11 contributors for this article] (2020). Bør beregning av cellegiftdose ved tarmkreft baseres på kroppssammensetning? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 140(8), p. 1–10. doi: 10.4045/tidsskr.19.0769.
• Smeby, Jørgen; Kryeziu, Kushtrim; Berg, Kaja Christine Graue; Eilertsen, Ina Andrassy; Eide, Peter Andreas Wold & Johannessen, Bjarne [Show all 11 contributors for this article] (2020). Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine. ISSN 2352-3964. 59:102923, p. 1–13. doi: 10.1016/j.ebiom.2020.102923. Full text in Research Archive
• Bergsland, Christian Holst; Bruun, Jarle; Guren, Marianne; Svindland, Aud; Bjørnslett, Merete Pauline & Smeby, Jørgen [Show all 16 contributors for this article] (2020). Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open. ISSN 2059-7029. 5:e001040(6), p. 1–12. doi: 10.1136/esmoopen-2020-001040. Full text in Research Archive
• Al-Haidari, Ghazwan Ahmed Dhia Eldin; Skovlund, Eva; Undseth, Christine; Rekstad, Bernt Louni; Larsen, Steinar & Åsli, Linn Merete [Show all 9 contributors for this article] (2020). Re-irradiation for recurrent rectal cancer – a single-center experience. Acta Oncologica. ISSN 0284-186X. 59(5), p. 534–540. doi: 10.1080/0284186X.2020.1725111.
• Frydenberg, Hanne; Harsem, Nina Kittelsen; Ofigsbø, Åsa; heid, hanne skoglund; Brandengen, Morten & Kaasa, Stein [Show all 7 contributors for this article] (2020). Chemotherapy During Pregnancy for Advanced Colon Cancer: A Case Report. Clinical colorectal cancer. ISSN 1533-0028. 19(2), p. 141–144. doi: 10.1016/j.clcc.2020.02.013. Full text in Research Archive
• Guren, Marianne Grønlie (2019). The global challenge of colorectal cancer. The Lancet Gastroenterology and Hepatology. ISSN 2468-1253. 4(12), p. 894–895. doi: 10.1016/S2468-1253(19)30329-2.
• Ben-Aharon, Irit; Goshen-Lago, Tal; Fontana, Elisa; Smyth, Elizabeth; Guren, Marianne Grønlie & Caballero, Carmela [Show all 7 contributors for this article] (2019). Social networks for young patients with cancer: the time for system agility. The Lancet Oncology. ISSN 1470-2045. 20(6), p. 765–765. doi: 10.1016/S1470-2045(19)30346-8.
• Røhrl, Kari; Guren, Marianne; Astrup, Guro Lindviksmoen; Småstuen, Milada C & Rustøen, Tone (2019). High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study. European Journal of Oncology Nursing. ISSN 1462-3889. 44. doi: 10.1016/j.ejon.2019.101679.
• Brunsell, Tuva Høst; Sveen, Anita; Bjørnbeth, Bjørn Atle; Røsok, Bård Ingvald; Danielsen, Stine Aske & Brudvik, Kristoffer Watten [Show all 13 contributors for this article] (2019). High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases. Clinical colorectal cancer. ISSN 1533-0028. 19(1), p. 26–47. doi: 10.1016/j.clcc.2019.09.003. Full text in Research Archive
• Araghi, Marzieh; Soerjomataram, Isabelle; Bardot, Aude; Ferlay, Jacques; Cabasag, Citadel J. & Morrison, David S. [Show all 23 contributors for this article] (2019). Changes in colorectal cancer incidence in seven high-income countries: a population-based study. The Lancet Gastroenterology and Hepatology. ISSN 2468-1253. 4(7), p. 511–518. doi: 10.1016/S2468-1253(19)30147-5.
• Smeby, Jørgen; Sveen, Anita; Bergsland, Christian Holst; Eilertsen, Ina Andrassy; Danielsen, Stine Aske & Eide, Peter Andreas Wold [Show all 11 contributors for this article] (2019). Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open. ISSN 2059-7029. 4:e000523(3), p. 1–10. doi: 10.1136/esmoopen-2019-000523. Full text in Research Archive
• Brunsell, Tuva Høst; Cengija, Vanja; Sveen, Anita; Bjørnbeth, Bjørn Atle; Røsok, Bård Ingvald & Brudvik, Kristoffer Watten [Show all 10 contributors for this article] (2019). Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. European Journal of Surgical Oncology. ISSN 0748-7983. p. 1–7. doi: 10.1016/j.ejso.2019.07.017. Full text in Research Archive
• Rusten, Espen; Rekstad, Bernt Louni; Undseth, Christine; Klotz, Dagmar; Hernes, Eivor & Guren, Marianne Grønlie [Show all 7 contributors for this article] (2019). Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors. British Journal of Radiology (BJR). ISSN 0007-1285. 92:20181006(1097), p. 1–8. doi: 10.1259/bjr.20181006. Full text in Research Archive
• Smeby, Jørgen; Sveen, Anita; Eilertsen, Ina Andrassy; Danielsen, Stine Aske; Hoff, Andreas Midbøe & Eide, Peter Andreas Wold [Show all 12 contributors for this article] (2019). Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis. ISSN 2157-9024. 8:35(6), p. 1–8. doi: 10.1038/s41389-019-0141-3. Full text in Research Archive
• Røhrl, Kari; Guren, Marianne; Småstuen, Milada Cvancarova & Rustøen, Tone (2019). Symptoms during chemotherapy in colorectal cancer patients. Supportive Care in Cancer. ISSN 0941-4355. 27(8), p. 3007–3017. doi: 10.1007/s00520-018-4598-y.
• Majano, Sara Benitez; Girolamo, Chiara Di; Rachet, Bernard; Maringe, Camille; Guren, Marianne & Glimelius, Bengt [Show all 13 contributors for this article] (2018). Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. The Lancet Oncology. ISSN 1470-2045. 20(1), p. 74–87. doi: 10.1016/S1470-2045(18)30646-6.
• Sodergren, Samantha C.; Johnson, Colin D.; Gilbert, Alexandra; Tomaszewski, Krzysztof A.; Chu, William & Chung, Hans T. [Show all 15 contributors for this article] (2018). Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer. Radiotherapy and Oncology. ISSN 0167-8140. 126(2), p. 222–228. doi: 10.1016/j.radonc.2017.11.018.
• Guren, Marianne; Aagnes, Bjarte; Nygård, Mari; Dahl, Olav & Møller, Bjørn (2018). Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016. Clinical colorectal cancer. ISSN 1533-0028. p. 1–8. doi: 10.1016/j.clcc.2018.10.001.
• Bruun, Jarle; Sveen, Anita; Barros, Rita; Eide, Peter Andreas Wold; Eilertsen, Ina Andrassy & Kolberg, Matthias [Show all 14 contributors for this article] (2018). Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Molecular Oncology. ISSN 1574-7891. 12(9), p. 1639–1655. doi: 10.1002/1878-0261.12347. Full text in Research Archive
• Claassen, Yvette H.M.; Vermeer, Nina C.A.; Iversen, Lene H.; van Eycken, Elizabeth; Guren, Marianne & Mroczkowski, Pawel [Show all 19 contributors for this article] (2018). Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison. British Journal of Cancer. ISSN 0007-0920. 119, p. 517–522. doi: 10.1038/s41416-018-0215-6.
• Vermeer, Nina C.A.; Claassen, Yvette H.M.; Derks, Marloes G.M.; Iversen, Lene H.; van Eycken, Elizabeth & Guren, Marianne [Show all 18 contributors for this article] (2018). Treatment and survival of patients with colon cancer aged 80 years and older: a EURECCA international comparison. The Oncologist. ISSN 1083-7159. 24(8), p. 982–990. doi: 10.1634/theoncologist.2017-0551.
• Smeby, Jørgen; Sveen, Anita; Merok, Marianne Aarstad; Danielsen, Stine Aske; Eilertsen, Ina Andrassy & Guren, Marianne [Show all 9 contributors for this article] (2018). CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Annals of Oncology. ISSN 0923-7534. 29(5), p. 1227–1234. doi: 10.1093/annonc/mdy085. Full text in Research Archive
• Byskov, Camilla; Nyvang, lars; Guren, Marianne Grønlie; Spindler, Karen-Lise Garm & Muren, Ludvig (2017). The normal tissue sparing potential of an adaptive plan selection strategy for re-irradiation of recurrent rectal cancer. Physics and imaging in radiation oncology (PIRO). ISSN 2405-6316. 3, p. 43–48. doi: 10.1016/j.phro.2017.09.001.
• Labori, Knut Jørgen; Guren, Marianne; Brudvik, Kristoffer Watten; Røsok, Bård Ingvald; Waage, Anne & Nesbakken, Arild [Show all 10 contributors for this article] (2017). Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival. Colorectal Disease. ISSN 1462-8910. 19(8), p. 731–738. doi: 10.1111/codi.13622.
• Rusten, Espen; Rekstad, Bernt Louni; Undseth, Christine; Al-Haidari, Ghazwan Ahmed Dhia Eldin; Hanekamp, Bettina & Hernes, Eivor [Show all 9 contributors for this article] (2017). Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography. Radiation Oncology. ISSN 1748-717X. 12(147), p. 1–8. doi: 10.1186/s13014-017-0883-z.
• Åsli, Linn Merete; Johannessen, Tom Børge; Myklebust, Tor Åge; Møller, Bjørn; Eriksen, Morten Tandberg & Guren, Marianne (2017). Preoperative chemoradiotherapy for rectal cancer and impact on outcomes ? A population-based study. Radiotherapy and Oncology. ISSN 0167-8140. 123(3), p. 446–453. doi: 10.1016/j.radonc.2017.04.012.
• Thomsen, Maria; Guren, Marianne; Skovlund, Eva; Glimelius, Bengt; Hjermstad, Marianne Jensen & Johansen, Julia S. [Show all 12 contributors for this article] (2017). Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. European Journal of Cancer. ISSN 0959-8049. 81, p. 26–35. doi: 10.1016/j.ejca.2017.04.026.
• Astrup, Guro Lindviksmoen; Hofsø, Kristin; Bjordal, Kristin; Guren, Marianne; Vistad, Ingvild & Cooper, Bruce [Show all 8 contributors for this article] (2017). Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. Acta Oncologica. ISSN 0284-186X. 56(3), p. 462–470. doi: 10.1080/0284186X.2016.1273546.
• Røhrl, Kari; Guren, Marianne; Miaskowski, Christine; Cooper, Bruce A.; Diep, Lien My & Rustøen, Tone (2016). No Differences in Symptom Burden Between Colorectal Cancer Patients Receiving Curative Versus Palliative Chemotherapy. Journal of Pain and Symptom Management. ISSN 0885-3924. 52(4), p. 539–547. doi: 10.1016/j.jpainsymman.2016.04.008.
• Cameron, Marte; Kersten, Christian; Vistad, Ingvild; van Helvoirt, Rene; Weyde, Kjetil & Undseth, Christine [Show all 10 contributors for this article] (2016). Palliative pelvic radiotherapy for symptomatic rectal cancer–a prospective multicenter study. Acta Oncologica. ISSN 0284-186X. 55(12), p. 1400–1407. doi: 10.1080/0284186X.2016.1191666.
• Glimelius, Bengt; Myklebust, Tor Åge; Lundqvist, Kristina; Wibe, Arne & Guren, Marianne (2016). Two countries – Two treatment strategies for rectal cancer. Radiotherapy and Oncology. ISSN 0167-8140. 121(3), p. 357–363. doi: 10.1016/j.radonc.2016.11.010.
• Leon, Otilia; Guren, Marianne; Radu, Calin; Gunnlaugsson, Adalsteinn & Johnsson, Anders (2015). Phase i study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. European Journal of Cancer. ISSN 0959-8049. 51(18), p. 2740–2746. doi: 10.1016/j.ejca.2015.08.029.
• Labori, Knut Jørgen; Schulz, Anselm; Drolsum, Anders; Guren, Marianne; Kløw, Nils-Einar & Bjørnbeth, Bjørn Atle (2015). Radiofrequency ablation of unresectable colorectal liver metastases: trends in management and outcome during a decade at a single center. Acta Radiologica Open. ISSN 2058-4601. 4(7), p. 1–9. doi: 10.1177/2058460115580877.
• Guren, Marianne; Kørner, Hartwig; Pfeffer, Frank; Myklebust, Tor Åge; Eriksen, Morten Tandberg & Edna, Tom-Harald [Show all 23 contributors for this article] (2015). Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010. Acta Oncologica. ISSN 0284-186X. 54(10), p. 1714–1722. doi: 10.3109/0284186X.2015.1034876.
• Walters, Sarah; Benitez-Majano, Sara; Muller, Patrick; Coleman, Michel P.; Allemani, Claudia & Butler, John [Show all 12 contributors for this article] (2015). Is England closing the international gap in cancer survival? British Journal of Cancer. ISSN 0007-0920. 113(5), p. 848–860. doi: 10.1038/bjc.2015.265.
• Cameron, Marte; Kersten, Christian; Vistad, Ingvild; van Helvoirt, Rene; Weyde, Kjetil & Undseth, Christine [Show all 10 contributors for this article] (2015). Palliative pelvic radiotherapy for symptomatic incurable prostate cancer - A prospective multicenter study. Radiotherapy and Oncology. ISSN 0167-8140. 115(3), p. 314–320. doi: 10.1016/j.radonc.2015.05.021. Full text in Research Archive
• Leon, Otilia; Guren, Marianne; Hagberg, Oskar; Glimelius, Bengt; Dahl, Olav & Havsteen, Hanne [Show all 17 contributors for this article] (2014). Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiotherapy and Oncology. ISSN 0167-8140. 113(3), p. 352–358. doi: 10.1016/j.radonc.2014.10.002.
• Guren, Marianne; Undseth, Christine; Rekstad, Bernt Louni; Brandengen, Morten; Dueland, Svein & Spindler, Karen-Lise Garm [Show all 8 contributors for this article] (2014). Reirradiation of locally recurrent rectal cancer: A systematic review. Radiotherapy and Oncology. ISSN 0167-8140. 113(2), p. 151–157. doi: 10.1016/j.radonc.2014.11.021.

View all works in Cristin

• Ystgaard, Mari Fjørtoft; Myklebust, Tor Åge; Smeby, Jørgen; Larsen, Inger Kristin; Guren, Tormod Kyrre & Kure, Elin Wenche Hegland [Show all 10 contributors for this article] (2024). Incidence patterns of colorectal cancer in Norway 1993-2022 by age, site, and morphology.
• Meltzer, Sebastian; Negård, Anne; Hamre, Hanne Mari; Kersten, Christian; Hofsli, Eva & Guren, Marianne Grønlie [Show all 9 contributors for this article] (2022). Early radiologic signal of nivolumab responsiveness after short-course oxaliplatin-based chemotherapy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
• Rowsell, Alison; Sodergren, Samantha C.; Vassiliou, Vassilios; Darlington, Anne-Sophie; Guren, Marianne & Alkhaffaf, Bilal [Show all 9 contributors for this article] (2022). Correction to: Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences(Gastric Cancer, (2022), 25, 4, (665-677), 10.1007/s10120-022-01309-6). Gastric Cancer. ISSN 1436-3291. doi: 10.1007/s10120-022-01346-1.
• Ree, Anne Hansen; Hamre, Hanne Mari; Kersten, Christian; Hofsli, Eva; Guren, Marianne Grønlie & Sørbye, Halfdan [Show all 10 contributors for this article] (2021). Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.
• Grøndahl, Aurora Rosvoll; Huynh, Bao Ngoc; Moe, Yngve Mardal; Kaushal, Christine Kiran; Rusten, Espen & Tomic, Oliver [Show all 13 contributors for this article] (2021). Deep learning for automatic target volume delineation .
• Grøndahl, Aurora Rosvoll; Huynh, Bao Ngoc; Moe, Yngve Mardal; Kaushal, Christine Kiran; Rusten, Espen & Tomic, Oliver [Show all 12 contributors for this article] (2021). Deep learning-based automatic delineation of anal cancer gross tumour volume: A multimodality comparison of CT,PET and MRI.
• Grøndahl, Aurora Rosvoll; Huynh, Bao Ngoc; Moe, Yngve Mardal; Kaushal, Christine Kiran; Rusten, Espen & Tomic, Oliver [Show all 12 contributors for this article] (2021). Deep learning-based automatic delineation of anal cancer gross tumour volume: A multimodality comparison of CT, PET and MRI.
• Kalsnes, Joakim; Rusten, Espen; Abravan, Azadeh; Rekstad, Bernt Louni; Hernes, Eivor & Guren, Marianne [Show all 7 contributors for this article] (2019). Assessment of hematologic toxicity by 18F-fluorodeoxyglucose PET/CT in anal cancer patients following chemoradiation.
• Kørner, Hartwig; Guren, Marianne; Søreide, Jon Arne; Kørner, Leif; Søreide, Kjetil & Kvaløy, Jan Terje [Show all 7 contributors for this article] (2019). Non-curative treatment of patients with colorectal cancer – a national cohort study.
• Rusten, Espen; Rekstad, Bernt Louni; Undseth, Christine; Hernes, Eivor; Hanekamp, Bettina & Guren, Marianne [Show all 7 contributors for this article] (2019). Medical imaging of anal cancer and image-guided radiotherapy strategies .
• Kalsnes, Joakim; Rusten, Espen; Abravan, Azadeh; Rekstad, Bernt Louni; Hernes, Eivor & Guren, Marianne [Show all 7 contributors for this article] (2019). FDG-PET/CT-based assessment of hematologic toxicity in anal cancer patients following chemoradiation. Radiotherapy and Oncology. ISSN 0167-8140. 133, p. 1112–1112.
• Skingen, Vilde Eide; Rusten, Espen; Rekstad, Bernt Louni; Undseth, Christine; Guren, Marianne & Malinen, Eirik (2018). A patient-specific tumor control probability model based on total lesion glycolysis of anal cancer. Radiotherapy and Oncology. ISSN 0167-8140. 127, p. 1088–1088.
• Rusten, Espen; Rekstad, Bernt Louni; Undseth, Christine; Hernes, Eivor; Guren, Marianne & Malinen, Eirik (2018). Prediction of anal carcinoma chemoradiotherapy outcome by a new PET-based biomarker. Radiotherapy and Oncology. ISSN 0167-8140. 127, p. 814–814.
• Støen, Ingvild; Rusten, Espen; Rekstad, Bernt Louni; Undseth, Christine; Al-Haidari, Ghazwan Ahmed Dhia Eldin & Hellebust, Taran Paulsen [Show all 8 contributors for this article] (2017). Optimal threshold for PET-based autocontouring of boost volume for radiotherapy of anal carcinoma.
• Skingen, Vilde Eide; Rekstad, Bernt Louni; Rusten, Espen; Undseth, Christine; Hellebust, Taran Paulsen & Guren, Marianne [Show all 7 contributors for this article] (2017). PET-based dose painting of anal carcinoma and implications for adaptive approaches.
• Malinen, Eirik; Rusten, Espen; Hernes, Eivor & Guren, Marianne (2017). Positron emission tomography in radiotherapy of anal cancer.
• Rusten, Espen; Rekstad, Bernt Louni; Undseth, Christine; Al-Haidari, Ghazwan Ahmed Dhia Eldin; Hanekamp, Bettina & Hernes, Eivor [Show all 9 contributors for this article] (2016). Target delineation of anal cancer based on MR or PET – an inter-observer, inter-modality study. Radiotherapy and Oncology. ISSN 0167-8140. 119, p. 336–337.
• Malinen, Eirik & Guren, Marianne (2016). Forskning innen bildeveiledet strålebehandling av analkreft.
• Røhrl, Kari; Guren, Marianne & Rustøen, Tone (2015). Symptom burden in colorectal cancer patient at start of chemotherapy.
• Rusten, Espen; Rekstad, Bernt Louni; Undseth, Christine; Hernes, Eivor; Guren, Marianne & Malinen, Eirik (2015). Early radiotherapy response monitoring of anal carcinoma with 18F-FDG-PET.
• Rekstad, Bernt Louni; Rusten, Espen; Undseth, Christine; Arnesen, Marius Røthe; Hellebust, Taran Paulsen & Holmboe, Laila Kampen Dajani [Show all 8 contributors for this article] (2015). Anal carcinoma – a candidate for FDG-PET guided high-dose simultaneously integrated boost .

View all works in Cristin